Investment Rating - The report maintains a "Buy" rating for the company, with a target price not specified [6][17]. Core Views - The company experienced a significant decline in revenue and net profit in the first half of 2025, with revenue at 358 million yuan, down 18.88% year-on-year, and net profit at 6 million yuan, down 80.99% year-on-year [1][4]. - The company is increasing its investment in Shanghai Huilun Pharmaceutical to enhance its innovation and research capabilities, raising its stake from 14.5971% to 15.4567% [1][3]. Financial Performance - In H1 2025, the company's gynecological products generated 266 million yuan in revenue, down 16.61% year-on-year, while urological products and heat-clearing and detoxifying products saw declines of 26.8% and 23.04%, respectively [2]. - The company has adjusted its revenue forecasts for 2025-2026 from 1.192 billion yuan and 1.339 billion yuan to 631 million yuan and 669 million yuan, respectively [4][5]. Research and Development - The company has a robust pipeline of traditional Chinese medicine innovations, focusing on various therapeutic areas, including bacterial vaginosis and male health maintenance [3]. - Huilun Pharmaceutical, in which the company holds a stake, is developing nearly 20 small molecule innovative drugs, with several expected to enter clinical phases by the end of 2025 [3]. Financial Projections - The company's projected net profit for 2025 is 21 million yuan, down from previous estimates of 116 million yuan and 134 million yuan for 2025 and 2026, respectively [4][5]. - The earnings per share (EPS) is projected to decline to 0.09 yuan in 2025, with a gradual recovery expected in subsequent years [5][10].

Core Viewpoint - New Tian Pharmaceutical continues to face declining performance in the first half of the year, with both revenue and net profit experiencing significant drops, primarily due to rising raw material costs and a noticeable decrease in product sales [2][4]. Financial Performance - The company reported a revenue of approximately 358 million yuan, a year-on-year decrease of 18.88% [4]. - Net profit attributed to shareholders was about 5.77 million yuan, down 80.99% year-on-year [4]. - The sales of gynecological products, which account for over 70% of revenue, fell by 16.61% [4][5]. Product Sales Breakdown - Gynecological products generated approximately 266 million yuan, representing a 16.61% decline [5]. - Urological products saw a revenue drop of 26.8%, totaling around 61 million yuan [5]. - Revenue from heat-clearing and detoxifying products decreased by 23.04%, amounting to approximately 28 million yuan [5]. - Other product categories experienced a 7% increase in revenue, totaling about 3.61 million yuan, but this only accounted for 1.01% of total revenue [4][5]. Cost and Expense Management - Rising raw material prices have been a persistent issue, with raw material costs accounting for 58.35% of total costs in 2023 [7]. - The company has been actively reducing sales expenses, with a 17.79% decrease in 2023 and a 15.06% decrease in 2024 [10]. - In the first half of 2025, sales expenses were approximately 159 million yuan, down 11.61% year-on-year [10]. Regulatory and Ethical Concerns - New Tian Pharmaceutical's subsidiary faced allegations of commercial bribery, which has led to increased scrutiny and pressure on sales strategies [9]. - The company has acknowledged the situation but has not provided detailed public comments on the allegations [9].